IDEXX Laboratories's total inventories for the quarter that ended in Mar. 2026 was €331 Mil. IDEXX Laboratories's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Mar. 2026 was €327 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. IDEXX Laboratories's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was €-10.75.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
IDEXX Laboratories's Days Inventory for the
three
months ended in Mar. 2026 was 82.43.
Inventory Turnover measures how fast the company turns over its inventory within a year.
IDEXX Laboratories's Inventory Turnover for the quarter that ended in Mar. 2026 was 1.11.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
IDEXX Laboratories's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.33.
IDEXX Laboratories (FRA:IX1) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
IDEXX Laboratories's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
IDEXX Laboratories's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
IDEXX Laboratories Total Inventories Related Terms
IDEXX Laboratories Total Inventories Historical Data
* Premium members only.
The historical data trend for IDEXX Laboratories's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
IDEXX Laboratories (FRA:IX1) has a Total Inventories of €331 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for IDEXX Laboratories and its competitors.
Is IDEXX Laboratories' Total Inventories too high?
IDEXX Laboratories' current Total Inventories is €331 Mil. Overall, IDEXX Laboratories has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IDEXX Laboratories' Total Inventories compare to A and WAT?
IDEXX Laboratories' Total Inventories of €331 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Medical Diagnostics & Research company?
A good Total Inventories depends on the Medical Diagnostics & Research industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for IDEXX Laboratories and its competitors. IDEXX Laboratories's current Total Inventories is €331 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEXX Laboratories stock overvalued right now?
Based on GuruFocus' analysis, IDEXX Laboratories (FRA:IX1) is currently considered Modestly Undervalued. The stock's GF Value™ is €552.99, compared to a current price of €473.80 — trading 14.3% below its estimated fair value. The current Total Inventories is €331 Mil. IDEXX Laboratories' overall GF Score™ is 96/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For IDEXX Laboratories (FRA:IX1), the current Total Inventories is €331 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IDEXX Laboratories (FRA:IX1) Overvalued in 2026?
Based on GuruFocus' analysis, IDEXX Laboratories stock appears to be undervalued.
The current stock price of €473.80 is trading 14.3% below its estimated GF Value™ of €552.99.
GuruFocus considers IDEXX Laboratories to be Modestly Undervalued.
Key valuation signals for FRA:IX1:
Total Inventories: €331 Mil
GF Value™: €552.99 vs. price of €473.80 (14.3% below fair value)
No single metric tells the full story. See the FRA:IX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
96GF Score
Get the complete analysis for FRA:IX1
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:IX1 has been successfully added to your 
